{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:47Z","timestamp":1772119547813,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016815","name":"Third Coast Center for AIDS Research","doi-asserted-by":"publisher","award":["P30 AI117943"],"award-info":[{"award-number":["P30 AI117943"]}],"id":[{"id":"10.13039\/100016815","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pre-exposure prophylaxis (PrEP) is an effective yet underutilized tool for HIV prevention. We examined opportunities for prescribing PrEP at two large, urban, academic healthcare institutions. We analyzed electronic medical record data for 1\/1\/2015-12\/31\/2021 among patients\u2009\n                    <jats:italic>\u2265<\/jats:italic>\n                    \u200918 years of age, with\n                    <jats:italic>\u2265<\/jats:italic>\n                    \u20091 negative HIV test with indications for PrEP. Eligible encounters were six months after a sexually transmitted infection, or when injection drug use (IDU) was documented. We categorized encounter setting, including the emergency department (ED) and obstetrics and gynecology\/women\u2019s health (OBGYN) department. We performed logistic mixed effects regression, reporting odds ratios and confidence intervals (OR, aOR, 95% CI). Overall, 9644 people contributed 53,031 encounters with 4653 PrEP prescriptions. The two institutions had different patient population demographics, with institution A having a higher proportion of women, patients aged 18\u201324, and non-Hispanic Blacks (NHB), and institution B having a higher proportion of men who have sex with men (MSM), non-Hispanic Whites (NHW), and Hispanic\/Latinos. Adjusted models found lower odds of PrEP prescriptions for NHB (aOR 0.21 [0.15, 0.29]), Hispanic\/Latino (aOR 0.53 [0.37, 0.76]), heterosexual women (aOR 0.10 [0.06, 0.17]), IDU (aOR 0.01 [0.001, 0.08]), and encounters at the ED or OBGYN (0.14 [0.06, 0.31]). Increased odds of PrEP prescription were seen among NHW (aOR 4.85 [3.45, 6.82]), MSM (aOR 24.87 [15.79, 39.15]), and patients at institution B (aOR 1.78 [1.25, 2.53]). Institution A contained people historically underrepresented in PrEP prescriptions, while institution B accounted for most PrEP prescriptions. Opportunities exist to improve equity in PrEP prescriptions among demographic groups and in hospital settings.\n                  <\/jats:p>","DOI":"10.1007\/s10461-025-04767-y","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:12:42Z","timestamp":1749503562000},"page":"3162-3171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding Opportunities for Prescribing Pre-exposure Prophylaxis at Two Academic Medical Centers in a High Priority Jurisdiction for Ending the HIV Epidemic"],"prefix":"10.1007","volume":"29","author":[{"given":"Moira C.","family":"McNulty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"McGuckin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-9763","authenticated-orcid":false,"given":"Eleanor E.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-6669","authenticated-orcid":false,"given":"Joseph A.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-9620","authenticated-orcid":false,"given":"Samantha A.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Giurcanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica P.","family":"Ridgway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad J.","family":"Achenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"9","key":"4767_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the united States. JAMA. 2019;321(9):844\u20135.","journal-title":"JAMA"},{"key":"4767_CR2","unstructured":"Getting to Zero Illinois. 2019\u20132023 Plan. https:\/\/gtzillinois.hiv\/wp-content\/uploads\/2019\/06\/GTZ-IL-plan-English-06062019.pdf. Accessed 1 May 2025."},{"key":"4767_CR3","unstructured":"EHE Plans and Websites: NASTAD. 2023. nastad.org\/resources\/ehe-plans-and-websites. Accessed 1 May 2025."},{"issue":"12","key":"4767_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.annepidem.2018.05.003","volume":"28","author":"DK Smith","year":"2018","unstructured":"Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race\/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850\u2013e79.","journal-title":"Ann Epidemiol"},{"issue":"22","key":"4767_CR5","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.2019.6390","volume":"321","author":"DK Owens","year":"2019","unstructured":"Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Preexposure prophylaxis for the prevention of HIV infection: US preventive services task force recommendation statement. JAMA. 2019;321(22):2203\u201313.","journal-title":"JAMA"},{"key":"4767_CR6","unstructured":"US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States\u20142017 update: a clinical practice guideline. CDC. 2021. https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2017.pdf. Accessed 1 May 2025."},{"key":"4767_CR7","first-page":"100738","volume":"33","author":"PS Sullivan","year":"2024","unstructured":"Sullivan PS, DuBose SN, Castel AD, Hoover KW, Juhasz M, Guest JL, et al. Equity of PrEP uptake by race, ethnicity, sex and region in the United States in the first decade of PrEP: a population-based analysis. Lancet Reg Health Am. 2024;33:100738.","journal-title":"Lancet Reg Health Am"},{"issue":"4","key":"4767_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jama.2020.7312","volume":"324","author":"HJ Song","year":"2020","unstructured":"Song HJ, Squires P, Wilson D, Lo-Ciganic W-H, Cook RL, Park H. Trends in HIV preexposure prophylaxis prescribing in the United States, 2012\u20132018. JAMA. 2020;324(4):395\u20137.","journal-title":"JAMA"},{"key":"4767_CR9","unstructured":"Expanding PrEP Coverage in the United States to Achieve EHE Goals: CDC NCHHSTP. 2023. https:\/\/www.cdc.gov\/nchhstp\/director-letters\/expanding-prep-coverage.html. Accessed 1 May 2025."},{"key":"4767_CR10","unstructured":"America\u2019s HIV Epidemic Analysis Dashboard. 2022. https:\/\/ahead.hiv.gov\/. Accessed 1 May 2025."},{"issue":"18","key":"4767_CR11","first-page":"1786","volume":"326","author":"BM Kuehn","year":"2021","unstructured":"Kuehn BM. Low PrEP awareness, referrals for black, Hispanic, and Latino people. JAMA. 2021;326(18):1786.","journal-title":"JAMA"},{"issue":"12","key":"4767_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.annepidem.2018.06.005","volume":"28","author":"AJ Siegler","year":"2018","unstructured":"Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841\u20139.","journal-title":"Ann Epidemiol"},{"issue":"5","key":"4767_CR13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s10461-016-1625-1","volume":"21","author":"AE Petroll","year":"2017","unstructured":"Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256\u201367.","journal-title":"AIDS Behav"},{"issue":"7","key":"4767_CR14","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s10461-019-02411-0","volume":"23","author":"K Schueler","year":"2019","unstructured":"Schueler K, Ferreira M, Nikolopoulos G, Skaathun B, Paraskevis D, Hatzakis A, et al. Pre-exposure prophylaxis (PrEP) awareness and use within high HIV transmission networks. AIDS Behav. 2019;23(7):1893\u2013903.","journal-title":"AIDS Behav"},{"issue":"3","key":"4767_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/apc.2019.0189","volume":"34","author":"B Pleuhs","year":"2020","unstructured":"Pleuhs B, Quinn KG, Walsh JL, Petroll AE, John SA. Health care provider barriers to HIV pre-exposure prophylaxis in the United States: a systematic review. AIDS Patient Care STDS. 2020;34(3):111\u201323.","journal-title":"AIDS Patient Care STDS"},{"issue":"S1","key":"4767_CR16","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1097\/QAI.0000000000002974","volume":"90","author":"AK Johnson","year":"2022","unstructured":"Johnson AK, Pyra M, Devlin S, Uvin AZ, Irby S, Blum C, et al. Provider perspectives on factors affecting the PrEP care continuum among black cisgender women in the Midwest United States: applying the consolidated framework for implementation research. J Acquir Immune Defic Syndr. 2022;90(S1):S141\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"4767_CR17","first-page":"276","volume":"99","author":"J Babiarz","year":"2023","unstructured":"Babiarz J, Nix CD, Bowden S, Roberts R. Insufficient preparation: an assessment of primary care prescribing habits and use of pre-exposure prophylaxis in patients at risk of HIV acquisition at a single medical centre. Sex Transm Infect. 2023;99(4):276\u20138.","journal-title":"Sex Transm Infect"},{"issue":"3","key":"4767_CR18","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/QAI.0000000000002767","volume":"88","author":"AM Agovi","year":"2021","unstructured":"Agovi AM, Anikpo I, Cvitanovich MJ, Fasanmi EO, Ojha RP, Marcus JL. Brief report: HIV pre-exposure prophylaxis prescribing in an urban Safety-Net health system. J Acquir Immune Defic Syndr. 2021;88(3):e17\u201321.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4767_CR19","doi-asserted-by":"publisher","first-page":"215013192312017","DOI":"10.1177\/21501319231201784","volume":"14","author":"T Drallmeier","year":"2023","unstructured":"Drallmeier T, Salas J, Keegan Garrett E, Meyr A, Tucker J, Scherrer JF. Differences between general internal medicine and family medicine physicians\u2019 initiation of pre-exposure prophylaxis. J Prim Care Community Health. 2023;14:21501319231201784.","journal-title":"J Prim Care Community Health"},{"issue":"3","key":"4767_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/09564624211048671","volume":"33","author":"SE McLaughlin","year":"2022","unstructured":"McLaughlin SE, Kapadia F, Greene RE, Pitts R. Capturing missed HIV pre-exposure prophylaxis opportunities-sexually transmitted infection diagnoses in the emergency department. Int J STD AIDS. 2022;33(3):242\u20136.","journal-title":"Int J STD AIDS"},{"key":"4767_CR21","unstructured":"AIDSVu Releases New Data Highlighting Ongoing Inequities in PrEP Use among Black and Hispanic People and across Regions of the Country: AIDSVu. 2023. https:\/\/aidsvu.org\/news-updates\/news-updates-aidsvu-releases-new-data-highlighting-ongoing-inequities-in-prep-use-among-black-and-hispanic-people-and-across-regions-of-the-county\/. Accessed 1 May 2025."},{"issue":"1","key":"4767_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/OLQ.0000000000001265","volume":"48","author":"C Yumori","year":"2021","unstructured":"Yumori C, Zucker J, Theodore D, Chang M, Carnevale C, Slowikowski J, et al. Women are less likely to be tested for HIV or offered preexposure prophylaxis at the time of sexually transmitted infection diagnosis. Sex Transm Dis. 2021;48(1):32\u20136.","journal-title":"Sex Transm Dis"},{"issue":"Suppl 1","key":"4767_CR23","doi-asserted-by":"publisher","first-page":"S396","DOI":"10.1093\/ofid\/ofy210.1129","volume":"5","author":"R Pitts","year":"2018","unstructured":"Pitts R, Holzman R, Greene R, Lam E, Carmody E, Braithwaite S. 1296. Potential use of sexually transmitted infection (STI) testing for expanding HIV pre-exposure prophylaxis (PrEP) at an urban hospital center. Open Forum Infect Dis. 2018;5(Suppl 1):S396.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"4767_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/JNC.0000000000000147","volume":"31","author":"DA Theodore","year":"2020","unstructured":"Theodore DA, Zucker J, Carnevale C, Grant W, Adan M, Borsa A, et al. Pre-exposure prophylaxis use among predominantly African American and Hispanic women at risk for HIV acquisition in New York City. J Assoc Nurses AIDS Care. 2020;31(1):110\u20134.","journal-title":"J Assoc Nurses AIDS Care"},{"key":"4767_CR25","doi-asserted-by":"crossref","unstructured":"Bien CH, Patel VV, Blackstock OJ, Felsen UR. Reaching key populations: PrEP uptake in an urban health care system in the Bronx, New York. AIDS Behav. 2017;21(5):1309-14.","DOI":"10.1007\/s10461-016-1663-8"},{"issue":"1","key":"4767_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1186\/s12879-023-08719-6","volume":"23","author":"AK Johnson","year":"2023","unstructured":"Johnson AK, Devlin S, Haider S, Oehler C, Rivera J, Alvarez I, Ridgway J. Evaluation of multiple data sources for predicting increased need for HIV prevention among cisgender women: understanding missed opportunities for Pre-exposure prophylaxis (PrEP). BMC Infect Dis. 2023;23(1):781.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"4767_CR27","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s10461-017-1979-z","volume":"22","author":"SK Calabrese","year":"2018","unstructured":"Calabrese SK, Earnshaw VA, Krakower DS, Underhill K, Vincent W, Magnus M, et al. A closer look at racism and heterosexism in medical students\u2019 clinical decision-making related to HIV pre-exposure prophylaxis (PrEP): implications for PrEP education. AIDS Behav. 2018;22(4):1122\u201338.","journal-title":"AIDS Behav"},{"issue":"5","key":"4767_CR28","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s10461-021-03495-3","volume":"26","author":"SK Calabrese","year":"2022","unstructured":"Calabrese SK, Kalwicz DA, Modrakovic D, Earnshaw VA, Edelman EJ, Bunting SR, et al. An experimental study of the effects of patient race, sexual orientation, and injection drug use on providers\u2019 PrEP-Related clinical judgments. AIDS Behav. 2022;26(5):1393\u2013421.","journal-title":"AIDS Behav"},{"issue":"2","key":"4767_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cptl.2023.02.019","volume":"15","author":"SR Bunting","year":"2023","unstructured":"Bunting SR, Feinstein BA, Bertram C, Hazra A, Sheth NK, Garber SS. Effects of knowledge and implicit biases on pharmacy students\u2019 decision-making regarding pre-exposure prophylaxis for HIV prevention: a vignette-based experimental study. Curr Pharm Teach Learn. 2023;15(2):139\u201348.","journal-title":"Curr Pharm Teach Learn"},{"issue":"10","key":"4767_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/apc.2018.0066","volume":"32","author":"EA Almirol","year":"2018","unstructured":"Almirol EA, McNulty MC, Schmitt J, Eavou R, Taylor M, Tobin A, et al. Gender differences in HIV testing, diagnosis, and linkage to care in healthcare settings: identifying African American women with HIV in Chicago. AIDS Patient Care STDS. 2018;32(10):399\u2013407.","journal-title":"AIDS Patient Care STDS"},{"key":"4767_CR31","unstructured":"Diagnoses of HIV infection in the United States and dependent areas. 2019. CDC; 2021."},{"issue":"3","key":"4767_CR32","doi-asserted-by":"publisher","first-page":"e0300540","DOI":"10.1371\/journal.pone.0300540","volume":"19","author":"SA Devlin","year":"2024","unstructured":"Devlin SA, Johnson AK, Stanford KA, Haider S, Ridgway JP. There hasn\u2019t been a push to identify patients in the emergency department-Staff perspectives on automated identification of candidates for pre-exposure prophylaxis (PrEP): a qualitative study. PLoS ONE. 2024;19(3):e0300540.","journal-title":"PLoS ONE"},{"issue":"4","key":"4767_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/QAI.0000000000003376","volume":"95","author":"JE Volk","year":"2024","unstructured":"Volk JE, Leyden WA, Lea AN, Lee C, Donnelly MC, Krakower DS, et al. Using electronic health records to improve HIV preexposure prophylaxis care: a randomized trial. J Acquir Immune Defic Syndr. 2024;95(4):362\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6s","key":"4767_CR34","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1097\/ACM.0000000000005182","volume":"98","author":"A Hazra","year":"2023","unstructured":"Hazra A, Stanford K, Schneider J, Davis A. Introducing a sexual wellness clinic to an at-risk population through the emergency department. Acad Med. 2023;98(6s):S60\u20132.","journal-title":"Acad Med"},{"issue":"4","key":"4767_CR35","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2352-3018(22)00036-4","volume":"9","author":"JL Marcus","year":"2022","unstructured":"Marcus JL, Krakower DS. Making PrEP easy. Lancet HIV. 2022;9(4):e226\u20138.","journal-title":"Lancet HIV"},{"issue":"6","key":"4767_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11904-020-00528-9","volume":"17","author":"AJ Siegler","year":"2020","unstructured":"Siegler AJ, Steehler K, Sales JM, Krakower DS. A review of HIV pre-exposure prophylaxis streamlining strategies. Curr HIV\/AIDS Rep. 2020;17(6):643\u201353.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"4767_CR37","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.dadr.2024.100288","volume":"13","author":"T Verinumbe","year":"2024","unstructured":"Verinumbe T, Lucas GM, Zook K, Weir B, Landry M, Page KR, et al. Associations of HIV pre-exposure prophylaxis (PrEP) indication, HIV risk perception and unwillingness to use PrEP among people who inject drugs in Baltimore, MD. Drug Alcohol Depend Rep. 2024;13:100288.","journal-title":"Drug Alcohol Depend Rep"},{"key":"4767_CR38","doi-asserted-by":"crossref","unstructured":"Price DM, Garretson M, Cai X, Miah F, Scanlin K, Blackstock O, Edelstein Z. Knowledge and attitudes about HIV pre-exposure prophylaxis among sexually active black and latina cisgender women: findings from the 2017 and 2018 New York City Sexual Health Survey. AIDS Patient Care STDS. 2024;38(9):428\u201337.","DOI":"10.1089\/apc.2024.0142"},{"key":"4767_CR39","doi-asserted-by":"crossref","unstructured":"Mathurin A, Tafuto B, Lechner DW. Barriers to HIV pre-exposure prophylaxis use among women in the US: a systematic literature review. Princ Pract Clin Res. 2024;10(1).","DOI":"10.21801\/ppcrj.2024.101.4"},{"issue":"11 Suppl","key":"4767_CR40","first-page":"S207","volume":"30","author":"P Sullivan","year":"2024","unstructured":"Sullivan P, Brixner D, Lam JT, Hsiao A. Overcoming barriers to HIV prevention: population health considerations on optimizing PrEP access. Am J Manag Care. 2024;30(11 Suppl):S207\u201315.","journal-title":"Am J Manag Care"},{"key":"4767_CR41","doi-asserted-by":"crossref","unstructured":"Boudreaux J, Valdebenito CM, Pichon LC. Identifying access barriers to PrEP among cisgender Black\/African American women in the United States: a systematic review of the literature. Healthcare (Basel). 2025;13(1).","DOI":"10.3390\/healthcare13010086"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04767-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04767-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04767-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T09:11:10Z","timestamp":1759223470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04767-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4767"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04767-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.25.24310992","asserted-by":"object"}]},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"10 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Moira McNulty has served on an advisory board for Gilead Sciences. Jessica Ridgway has received consulting fees from Gilead Sciences. Anu Hazra receives research support from Gilead Sciences and has served on advisory boards for Gilead Sciences and ViiV Healthcare. Eleanor Friedman has received funds as part of a Gilead FOCUS grant. All other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}